NasdaqGS - Nasdaq Real Time Price • USD
Legend Biotech Corporation (LEGN)
At close: May 10 at 4:00 PM EDT
After hours: May 10 at 7:53 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 10 | 10 |
| Avg. Estimate | -0.34 | -0.44 | -1.47 | -0.62 |
| Low Estimate | -0.75 | -0.77 | -2.73 | -1.71 |
| High Estimate | -0.08 | -0.09 | -0.5 | 0.42 |
| Year Ago EPS | -0.68 | -1.14 | -2.94 | -1.47 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 17 | 16 |
| Avg. Estimate | 152.63M | 126.37M | 579.24M | 1.08B |
| Low Estimate | 80M | 85M | 450M | 841.7M |
| High Estimate | 202.5M | 168.2M | 676.87M | 1.53B |
| Year Ago Sales | 36.34M | 73.33M | 285.14M | 579.24M |
| Sales Growth (year/est) | 320.10% | 72.30% | 103.10% | 87.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.78 | -0.6 | -0.68 | -0.83 |
| EPS Actual | -0.68 | -1.14 | -0.34 | -0.8 |
| Difference | 0.1 | -0.54 | 0.34 | 0.03 |
| Surprise % | 12.80% | -90.00% | 50.00% | 3.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.34 | -0.44 | -1.47 | -0.62 |
| 7 Days Ago | -0.34 | -0.44 | -1.47 | -0.62 |
| 30 Days Ago | -0.35 | -0.46 | -1.52 | -0.65 |
| 60 Days Ago | -0.32 | -0.5 | -2 | -0.56 |
| 90 Days Ago | -0.62 | -0.62 | -1.53 | -0.47 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LEGN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 50.00% | -- | -- | 8.40% |
| Next Qtr. | 61.40% | -- | -- | 11.90% |
| Current Year | 50.00% | -- | -- | 5.60% |
| Next Year | 57.80% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -- | -- | -- | 11.05% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/9/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/23/2024 |
| Upgrade | Scotiabank: Sector Perform to Sector Outperform | 4/17/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/16/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 4/3/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/1/2024 |
Related Tickers
BGNE BeiGene, Ltd.
161.13
-4.45%
ASND Ascendis Pharma A/S
133.46
+0.25%
PCVX Vaxcyte, Inc.
65.19
-0.58%
ARGX argenx SE
374.63
-2.07%
ACLX Arcellx, Inc.
49.74
-5.67%
KRYS Krystal Biotech, Inc.
154.76
-2.50%
CYTK Cytokinetics, Incorporated
62.10
-3.00%
ALNY Alnylam Pharmaceuticals, Inc.
150.47
-0.59%
FOLD Amicus Therapeutics, Inc.
9.23
-2.64%
BBIO BridgeBio Pharma, Inc.
29.10
+1.29%